



HAL
open science

Exploration of Bacterial Bottlenecks and *Streptococcus pneumoniae* Pathogenesis by CRISPRi-Seq

Xue Liu, Jacqueline Kimmey, Vincent de Bakker, Victor Nizet, Jan-Willem Veening

► To cite this version:

Xue Liu, Jacqueline Kimmey, Vincent de Bakker, Victor Nizet, Jan-Willem Veening. Exploration of Bacterial Bottlenecks and *Streptococcus pneumoniae* Pathogenesis by CRISPRi-Seq. *Cell Host & Microbe*, 2021, 29 (1), pp.107-120.e6. 10.1016/j.chom.2020.10.001 . inserm-03299441

HAL Id: inserm-03299441

<https://inserm.hal.science/inserm-03299441>

Submitted on 26 Jul 2021

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Exploration of bacterial bottlenecks and *Streptococcus pneumoniae* pathogenesis by CRISPRi-seq

Xue Liu^{a,1}, Jacqueline M. Kimmey^{b,c,1}, Vincent de Bakker^a, Victor Nizet^{b,d}, Jan-Willem Veening^{a,2,3}

^a Department of Fundamental Microbiology, Faculty of Biology and Medicine, University of Lausanne, Biophore Building, Lausanne 1015, Switzerland

^b Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, CA, United States.

^c Department of Microbiology and Environmental Toxicology, University of California, Santa Cruz, Santa Cruz, CA, United States

^d Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA, United States.

¹ These authors contributed equally to this work

² Twitter: @JWVeening

³ Correspondence: jan-willem.veening@unil.ch

Abstract

Streptococcus pneumoniae is a commensal bacterium of the human nasopharynx, but can cause harmful infections if it spreads to other parts of the body, such as pneumonia, sepsis or meningitis. To facilitate pathogenesis studies, we constructed a doxycycline-inducible pooled CRISPR interference (CRISPRi) library targeting all operons in prototypical *S. pneumoniae* strain D39V. Our library design allows fitness within the pool to be assessed by a one-step PCR reaction directly followed by Illumina sequencing (CRISPRi-seq). The doxycycline-inducible CRISPRi system is tightly controllable and suitable for both bottleneck exploration and evaluation of gene fitness *in vitro* and *in vivo*. Here, we applied CRISPRi-seq to identify genetic factors important for causing pneumococcal pneumonia. Mice were infected intratracheally with our CRISPRi library and bacteria collected at 24 h (from lung) and 48 h (from both lung and blood) post-infection. CRISPRi-seq showed a critical bottleneck at 48 h after intratracheal infection, with only a few bacteria surviving the brunt of the innate immune response to cause systemic infection. However, earlier at 24 h post-infection, many significant differences in gene fitness cost between *in vitro* and *in vivo* conditions were identified, including genes encoding known and putative novel virulence factors, genes essential only *in vivo*, and genes essential only *in vitro*. A key advantage of CRISPRi-seq over traditional transposon-based genetic screens is that all genes, including essential genes, can be tested for their role in virulence and pathogenicity. The approaches developed here should be generally applicable to study infection bottlenecks and *in vivo* fitness for other important human and animal pathogens.

Keywords: CRISPRi-seq, *Streptococcus pneumoniae*, bacterial pathogenesis, bottleneck, pneumonia

40 Introduction

41 *Streptococcus pneumoniae* is one of the most prevalent opportunistic human pathogens. The bacterium frequently
42 colonizes the human nasopharynx but can cause severe diseases when it invades normally sterile sites. Invasive
43 pneumococcal diseases, including pneumonia, sepsis, and meningitis, lead to millions of deaths per year (Weiser et
44 al., 2018). *S. pneumoniae* is the leading agent of bacterial pneumonia worldwide (van der Poll and Opal, 2009). The
45 pathogenesis of pneumococcal pneumonia involves complicated host-pathogen interactions, and while several key
46 virulence factors are well studied, it remains unknown if or how the majority of the bacterium's genome contributes
47 to disease progression. Murine *S. pneumoniae* infection is commonly studied for modeling clinically relevant stages
48 of disease including pneumonia and sepsis (Chiavolini et al., 2008). High-throughput identification of important
49 pneumococcal factors during the progression of bacterial pneumonia in the murine model can provide new
50 perspectives for understanding this leading human infectious disease.

51 Large-scale identification of *S. pneumoniae* virulence determinants has been attempted by signature-tagged
52 mutagenesis (STM) and Tn-seq studies (Chen et al., 2007; Hava and Camilli, 2002; Lau et al., 2001; Opijnen and
53 Camilli, 2012; van Opijnen et al., 2009), however, these approaches have certain technical limitations, including the
54 inability to investigate essential genes, and the fact that not all Tn-insertions result in gene inactivation thus requiring
55 large libraries to fully cover the genome. We previously harnessed an IPTG-inducible CRISPRi system for functional
56 study of essential genes in *S. pneumoniae* D39V *in vitro*, and with an arrayed CRISPRi library, we refined the essential
57 gene list and identified the function of several hypothetical proteins (Liu et al., 2017). This prior study showed the
58 power of CRISPR interference (CRISPRi) for functional gene analysis; however, it was laborious to handle the arrayed
59 library and the IPTG-inducible system was not ideal for *in vivo* studies, limiting its application scope. Based on these
60 considerations, we developed a tetracycline/doxycycline-inducible CRISPRi system for *S. pneumoniae* that is
61 applicable to both *in vitro* and *in vivo* studies. In addition, we constructed a pooled CRISPRi library targeting nearly
62 all operons of the prototypic *S. pneumoniae* strain D39V (Slager et al., 2018) that can readily be combined with
63 Illumina sequencing (herein referred to as CRISPRi-seq). This sgRNA library also covers core operons of other
64 pneumococcal strains, like R6 (estimated 87.9% of genetic elements covered), TIGR4 (75%), Hungary 19A-6
65 (72.3%), Taiwan 19F-14 (72.2%), 11A (69.6%), G54 (72.5%) (see supplementary text). While pooled CRISPRi
66 libraries have recently been reported for *Escherichia coli*, *Staphylococcus aureus*, *Vibrio natriegens* and
67 *Mycobacterium tuberculosis* (Cui et al., 2018; Jiang et al., 2020; Lee et al., 2019; Wang et al., 2018; de Wet et al.,
68 2018), they all used large pools of sgRNA targeting each gene multiple times, often leading to off targeting (Cui et
69 al., 2018). In addition, these libraries required very deep sequencing to obtain enough statistical power on the
70 abundance of each sgRNA in the population and are thus not well suited for conditions in which bottlenecks appear.
71 Here, we carefully selected a single sgRNA for every operon in *S. pneumoniae* D39V, thereby limiting off target
72 effects and reducing the pool of sgRNA required to cover the entire genome.

73 In the present study, we used a murine pneumonia model initiated by intratracheal infection with our pooled
74 library, followed by CRISPRi-seq to measure the relative fitness contribution of each operon in the *S. pneumoniae*
75 D39V genome. In addition to identifying genes associated with bacterial survival in the lung and blood niches, we
76 also identified an extreme bacterial bottleneck in progression from pneumonia to sepsis. Bottlenecks limit population

77 diversity, reminiscent of earlier work in which a small effective population of pneumococcal nasopharyngeal
78 colonization was observed (Li et al., 2013). In addition, prior reports provided a hint regarding a single-cell bottleneck
79 for bloodstream invasion and transmission, however these studies lacked resolution as they utilized only three isogenic
80 mutants (Gerlini et al., 2014; Kono et al., 2016). In contrast, our pooled CRISPRi library contains 1499 different
81 genetic markers coded by the various sgRNAs allowing precise measurement of bottlenecks. Our studies further
82 demonstrate a large variation between hosts, and ultimately in disease progression – even in genetically identical
83 inbred mice. Specifically, while an extreme bottleneck to bloodstream infection was observed in each mouse, the
84 number of individual unique bacterial “barcodes” detected in blood ranged from 0 – 10^7 in each mouse. This finding
85 is significant to our understanding of pneumococcal disease, given that in humans, the majority of *S. pneumoniae*
86 exposures *do not* lead to severe disease, and disease manifestations can vary within a host over time. Thus, these high-
87 resolution studies allow tracking of bacterial dynamics within a host, a first step towards demonstrating that no gene
88 is singularly responsible for “virulence” or “avirulence.” Rather, it appears likely that there are many possible
89 combinations through which the individual genes of the pneumococcal genome confer pathogenicity.

90


91 **Results**

92 **A tetracycline-inducible CRISPRi system in *S. pneumoniae* enables both *in vitro* and *in vivo* studies**

93 To enable the study of *S. pneumoniae* genes *in vivo*, we designed a tetracycline inducible (tet-inducible) CRISPRi
94 system. The two key elements of the CRISPRi system, *dcas9* and *sgRNA* were integrated into the pneumococcal
95 chromosome, driven by a tet-inducible promoter (P_{tet}) and a constitutive promoter (P_3), respectively (Figure 1A).
96 Constitutively expressed *tetR*, which encodes the tet-repressor, was codon optimized and integrated into the
97 chromosome to enable tet-inducible expression conferred by P_{tet} (Sorg et al., 2019). Here, doxycycline was used to
98 induce dCas9 expression because it has been extensively validated as tet inducer in rodent models due to its high
99 potency and excellent tissue penetration (Redelsperger et al., 2016). To alleviate growth stress caused by
100 doxycycline’s antimicrobial activity, TetM served as the antibiotic marker for *dcas9* chromosome integration. TetM
101 is a ribosome protection protein that confers tetracycline resistance by catalyzing the release of tetracycline and its
102 derivatives from the ribosome in a GTP-dependent manner (Burdett, 1996; Dönhöfer et al., 2012).

103

Liu et al., 22 April 2020 – *bioRxiv* submission



104
105

106 **Figure 1. A tet-inducible CRISPRi system in *S. pneumoniae*.** (A) The design of the tet-inducible CRISPRi system.
 107 The two key elements, *dcas9* and *sgRNA*, were integrated into the chromosome and driven by a tet-inducible promoter
 108 (P_{tet}) and a constitutive promoter (P3), respectively. With addition of the P_{tet} inducer, here doxycycline, a derivative
 109 of tetracycline, dCas9 is expressed and binds to the target under the guidance of a constitutively expressed sgRNA.
 110 The specific dCas9-sgRNA binding to the target gene acts as a transcriptional roadblock. P_{tet} is tightly controlled in
 111 the absence of the inducer, and expression of dCas9 is repressed. Without binding of dCas9-sgRNA, the target gene
 112 is transcribed. (B) The CRISPRi system was tested by targeting a constitutively expressed reporter gene, *luc*, which
 113 encodes firefly luciferase. The system was induced with doxycycline at different concentrations. Luciferase activity
 114 (RLU/OD) and cell density (OD595) were measured every 10 minutes. The values represent averages of three
 115 replicates with SEM. (C) Reporter strain to assess *in vivo* activity of the doxycycline-inducible CRISPRi system.
 116 Strain VL2351 constitutively expresses two fluorescent proteins, mNeonGreen and mScarlet-I, in which mNeonGreen
 117 is targeted by the sgRNA. Bacteria were collected from blood of mice on control or doxy-chow at 48 hpi and imaged
 118 with confocal microscopy in both the red and green channels. (D) Bacterial load at both lung and blood was
 119 enumerated by plating on agar plate. Each dot represents a single mouse. Mean with SEM was plotted. There is no
 120 significant (NS) difference between the bacterial load in control and doxycycline treated mice (Mann Whitney test).


121

122 The efficiency of the tet-inducible CRISPRi system was tested in both C+Y medium and in a mouse pneumonia model.
 123 A reporter strain expressing firefly luciferase (*luc*) under a constitutive promoter was used for the *in vitro* assay
 124 performed in C+Y medium. Efficiency of the tet-inducible CRISPRi system targeting *luc* was evaluated by monitoring
 125 luciferase activity in C+Y medium with different concentrations of doxycycline (Figure 1B). As little as 10 ng/ml

126 doxycycline was enough to strongly reduce (>20 fold) luciferase activity within 3 h, while 50 ng/ml doxycycline
127 yielded a maximum repression efficiency without causing growth retardation (Figure 1B). To test the functionality of
128 the tet-inducible CRISPRi system *in vivo*, a dual-fluorescent reporter strain was constructed that constitutively
129 expressed mNeonGreen and mScarlet-I. The CRISPRi system in this reporter strain was designed with an sgRNA
130 targeting the coding region of mNeonGreen. BALB/c mice were fed *ad libitum* with chow containing 200 ppm
131 doxycycline hyclate or control chow for 2 days prior to infection, then infected with the reporter strain by intratracheal
132 inoculation. At 48 h post infection (hpi), bacteria in blood samples were checked by confocal microscopy for both
133 green (mNeonGreen) and red (mScarlet-I) fluorescence. As expected, both mNeonGreen and mScarlet-I signals were
134 present in the sample harvested from mice fed with control chow, whereas the mNeonGreen signal was absent in mice
135 receiving doxycycline (Figure 1C). Specific inhibition of *S. pneumoniae* mNeonGreen expression in mice fed with
136 doxycycline confirmed functionality of the tet-inducible CRISPRi system *in vivo*. Finally, we verified that this dose
137 of doxycycline did not alter *S. pneumoniae* burden in blood or lungs at 24 hpi and 48 hpi (Figure 1D), giving us a tool
138 to regulate gene expression without interfering with bacterial survival.

139

Liu et al., 22 April 2020 – bioRxiv submission



140

141 **Figure 2. Workflow for construction of the pooled tet-inducible CRISPRi library.** (A) For the operons driven by
 142 primary transcriptional start site (pTSS) (Slager et al., 2018), an sgRNA in proximity of the pTSS was selected,
 143 resulting in 794 sgRNAs. For the genes not covered by pTSS operons, an sgRNA in proximity of the start codon was
 144 selected, resulting in 705 sgRNAs. In total, 1499 sgRNAs were selected targeting 2111 genetic elements out of the
 145 2,146 in *S. pneumoniae* D39V. (B) The vector for sgRNA cloning, named pPEPZ-sgRNAclone, was designed to
 146 enable high efficiency Golden Gate cloning, monitoring false positive ratio, and construction of Illumina library in a
 147 one-step PCR. SpecR is the spectinomycin resistant marker; NGS indicates key elements which allow construction of
 148 Illumina library by one-step PCR (see methods); P is the constitutive promoter which drives the expression of sgRNA;
 149 *mCherry* encodes a red fluorescent protein placed in the base-pairing region of sgRNA and flanked by a BsmBI site
 150 on each end; handle and ter represent the dCas9 handle binding region and terminator of sgRNA. *E. coli* with the
 151 pPEPZ-sgRNAclone form red colonies resulting from the expression of mCherry. BsmBI digestion of the vector
 152 produces ends that are compatible with the sgRNA oligo annealing in (C). (C) Forward and reverse oligos were

153 designed for each sgRNA containing 20 bp complementary to sgRNA and 4 nt overhangs compatible with the BsmBI
154 digested vector. The oligos were annealed and pooled together followed by 5' phosphorylation. (D) Ligation product
155 of the digested vector (B) with the sgRNA annealing (C) was transformed into *E. coli*. *E. coli* transformed with the
156 vector containing the sgRNA show white colonies due to replacement of *mCherry* with *sgRNA*. Among the more than
157 70,000 colonies (provides about 50 fold theoretical coverage of the sgRNA diversity) we collected, no red colony was
158 observed. The collected colonies were pooled together, and plasmids purified from the *E. coli* pool serves as an sgRNA
159 reservoir. (E) Pooled plasmid library was transformed into a *S. pneumoniae* D39V strain with chromosomally
160 integrated tet-inducible *dcas9*.

161

162 **A concise CRISPRi library with 1499 sgRNAs targeting the entire genome of *S. pneumoniae* D39V**

163 Due to the well-documented polar effects inherent to a CRISPRi system (Bikard et al., 2013; Liu et al., 2017; Peters
164 et al., 2016; Qi et al., 2013) we adopted this technique to study gene function at the operon level. The transcriptional
165 units of *S. pneumoniae* D39V are well annotated in our previous study (Slager et al., 2018)
166 (<https://veeninglab.com/pneumobrowse>). First, for each operon led by a primary transcriptional start site (pTSS), i.e.
167 the only or strongest TSS upstream of a feature (Slager et al. 2018), one specific sgRNA was selected with
168 preference for a short distance downstream from the TSS (Figure 2A), resulting in 794 unique sgRNAs. However,
169 the pTSS operons cover only about 65% of the genetic elements of *S. pneumoniae* D39V. For the genes not covered
170 within a pTSS operon, one specific sgRNA was selected to target the coding region closest to the start codon,
171 leading to the design of 705 further sgRNAs (Figure 2A). In total, 1499 sgRNAs were selected to target 2111 out of
172 2146 genetic elements of *S. pneumoniae* D39V. 35 elements are not included due to lack of a protospacer adjacent
173 motif (PAM) or localization in repeat regions on the chromosome (supplementary table S1). Potential (off-)targets
174 of sgRNAs are listed in supplementary table S2.

175 To enable efficient and convenient construction of sgRNA libraries, we engineered a new vector, pPEPZ-
176 sgRNAclone, that allows sgRNA insertion via Golden Gate cloning (Figure 2B). The *mCherry* reporter, flanked by a
177 BsmBI site on each end, was inserted at the position of the base-pairing region of the to-be-cloned sgRNA. *E. coli*
178 containing this parent vector produce red colonies on agar plates due to mCherry expression (Figure 2B). To facilitate
179 Illumina sequencing, key Illumina elements, including read 1, read 2, and adaptor sequences, were inserted flanking
180 the sgRNA transcriptional unit. A forward oligo and reverse oligo were synthesized encoding each designed sgRNA.
181 Each oligo was 24-nt, containing 20-nt of the base-pairing sequence of the sgRNA and a 4-nt overhang complementary
182 to BsmBI-digested pPEPZ-sgRNAclone (Figure 2C). The two oligos for each sgRNA were then annealed to produce
183 duplex DNA with 4-nt overhang on both ends, and then the collection of 1499 sgRNA duplex DNAs were pooled
184 together at equal molar concentrations, followed by phosphorylation. The phosphorylated sgRNA duplex DNA pool
185 was then ligated into BsmBI-digested pPEPZ-sgRNAclone, resulting in the replacement of *mCherry* with *sgRNA*
186 (Figure 2D). This ligation product could be directly transformed into *S. pneumoniae*. However, transformation into *E.*
187 *coli* was preferred to allow visual red/white screening of cloning efficiency: colonies containing the parental
188 (*mCherry*) vector are red, while colonies containing the *sgRNA* construct are white. In our study, no red colony showed
189 up among the 70,000 colonies, indicating this method was extremely efficient in producing a high quality sgRNA


190 pool. The *E. coli* library could also be used as a reservoir of sgRNAs for construction of reproducible CRISPRi
191 libraries among *S. pneumoniae* D39V strains with different genetic backgrounds (e.g. mutant strains) or to transform
192 other pneumococcal strains that contain the pPEPZ integration region, which is harbored by 64.21% of all sequenced
193 pneumococcal strains (Keller et al., 2019). The plasmid pool was then transformed into *S. pneumoniae* D39V with the
194 above described tet-inducible *dcas9* (Figure 2E). To compare the tet-inducible CRISPRi system to the IPTG-inducible
195 CRISPRi system previously published by our group (Liu et al., 2017), the sgRNA library was simultaneously
196 transformed into strain DCI23, which is *S. pneumoniae* D39V with IPTG-inducible *dcas9* (Liu et al., 2017).

197

198 **Benchmarking CRISPRi-seq with both tet- and IPTG-inducible libraries *in vitro***

199 CRISPRi screens with the constructed tet- and IPTG-inducible libraries were performed in C+Y medium, a standard
200 laboratory pneumococcal growth medium (Figure 3A). Libraries were induced for approximately 21 generations with
201 doxycycline and IPTG, respectively. The key Illumina elements, read 1 and read 2, inserted upstream and downstream
202 of the sgRNA transcription unit, provided the binding sequence for the PCR handle (Figure 3A). With this design, the
203 sgRNAs in the CRISPRi library could be amplified by a one-step PCR and sgRNAs subsequently quantified by
204 Illumina sequencing. Hence, this process was named CRISPRi-seq. Sequencing verified the presence of all 1499
205 sgRNAs in the uninduced samples of both tet- and IPTG-inducible libraries. The relative abundance of sgRNAs ranged
206 from 0.06 to 2.4 (Figure 3B), confirming that both CRISPRi libraries contain all designed sgRNAs. In uninduced
207 samples, no bias towards any of the sgRNAs was detected, as their counts appeared to be normally distributed (Figure
208 3B). In addition, the sgRNA abundance in the two libraries was highly correlated (Figure S1A), confirming that our
209 cloning strategy enabled repeatable transplantation of the sgRNA pool among parent strains with different genetic
210 backgrounds. Induction of dCas9 (CRISPRi ON) by either doxycycline or IPTG resulted in a similar change in sgRNA
211 profile (Figure 3B). The evaluated fitness, defined as the log₂ fold change of sgRNA abundance upon induction, was
212 highly consistent between the tet- and IPTG-inducible CRISPRi libraries (Figure 3C); only five sgRNAs exhibited a
213 statistically different abundance (log₂FC>1, *p*_{adj}<0.05) (Figure S1B). The sgRNAs that were significantly less
214 abundant upon dCas9 induction were categorized as targeting essential operons or genes. Likewise, sgRNAs that
215 increased in abundance upon induction were defined as targeting costly operons or genes, while sgRNAs that did not
216 change in abundance were defined as neutral. Based on this definition, 339 sgRNAs were defined as targeting essential
217 operons or genes, 1160 sgRNAs defined as neutral, and none defined as costly for *S. pneumoniae* growth *in vitro*
218 (supplementary table S3). Out of the 1499 sgRNAs, there were 1186 sgRNAs targeting individual genes, 162 sgRNAs
219 targeting two-gene operons, and 151 sgRNAs targeting operons with three or more genes. Among these, 248 single-
220 gene, 52 two-gene and 39 three-or-more-gene operons were found to be essential (Figure 3D). The majority of the
221 essential genes defined by our CRISPRi-seq results have been previously identified as essential or responsive by Tn-
222 seq studies (Liu et al., 2017; Opijnen and Camilli, 2012; van Opijnen et al., 2009), indicating high consistency between
223 the approaches (Figure S2) (supplementary table S4).

224



225
226 **Figure 3. Fitness evaluation of CRISPRi targets under laboratory conditions.** (A) Workflow of CRISPRi-seq.
227 The tet- or IPTG-inducible CRISPRi libraries were cultured in C+Y medium in the absence (CRISPRi-OFF) or in the
228 presence (CRISPRi-ON) of 10 ng/μl doxycycline or 1 mM IPTG. Bacteria were collected after approximately 21
229 generations of growth. Genomic DNA was isolated and used as a template for PCR. The forward oligo binds to
230 Illumina amplicon element read 1 and contains the Illumina P5 adapter sequence; the reverse oligo binds to read 2 and
231 contains the P7 adapter. Index 1 and index 2 were incorporated into the forward and reverse oligos respectively, for
232 barcoding of different samples (see supplementary table S9). (B) Violin plots showing the distribution of sgRNA
233 abundance in each samples. ‘-’ represents control samples without inducer; ‘+’ represents induced samples. The
234 abundance of sgRNA = 1499*(counts of sgRNA)/(total counts of all sgRNAs). (C) Correlation of the fitness of targets
235 evaluated by IPTG-inducible and tet-inducible libraries. The log₂FC, calculated with DEseq2, represents the fold
236 change of sgRNA frequency between the control sample and induced sample. (D) Refinement of essential and non-
237 essential genes of *S. pneumoniae* D39V by CRISPRi-seq. The sgRNAs were classified according to the number of
238 their targets. 1 gene represents the sgRNAs targeting single gene operons; 2 genes represents the sgRNAs targeting
239 two gene operons; >=3 genes represents the sgRNAs targeting operons with three or more genes.

240

241 **Bottlenecks and heterogeneity of *S. pneumoniae* in mouse pneumonia**

242 During early infection, due to general stresses placed upon the bacterium within the host, such as nutrient restriction
243 or innate immune system responses, a random part of the bacterial population might die off. This phenomenon is
244 called a bottleneck, and the corresponding bottleneck size is the effective population size that gives rise to the final,
245 post-bottleneck bacterial population that causes the infection. Such bottlenecks have been reported for pneumococcal
246 infection and transmission (Gerlini et al., 2014; Kono et al., 2016; Opijnen and Camilli, 2012), but precise estimations
247 of their sizes are lacking due to prior ineffective methodologies. A potential bottleneck in our pneumonia mouse model
248 could cause random sgRNA loss from the pool in the CRISPRi-seq screens, instead of depletion through biological

249 selection. This would introduce bias, in the sense that sgRNA depletion would no longer be an accurate proxy for gene
250 essentiality. However, our set-up does allow for assessing both the presence and size of such a bottleneck, since we
251 can accurately quantify the abundance of all 1499 strains in mice by Illumina sequencing, without inducing the
252 CRISPRi system. Any loss of sgRNAs should then be attributable to a bottleneck effect, whose size was previously
253 estimated on the basis of allele (here: sgRNA) frequencies in the pool before and after infection (Abel et al., 2015b).


254 To examine pneumococcal bottlenecks during a model of pneumonia, standard inbred adult BALB/c mice
255 were infected with the *S. pneumoniae* CRISPRi library via the intratracheal route and CRISPRi-seq was performed
256 from bacteria isolated at 48 hpi (from both lung and blood samples) and 24 hpi (only lung samples, as there are no
257 detectable bacteria in the bloodstream at this time point) (Figure 4A). At 24 hpi, bottleneck sizes were relatively large,
258 and covered more than 10-fold the library diversity in all samples except two (Figure 4B). Furthermore, estimated
259 bottleneck sizes appeared to be smaller for CRISPRi-induced samples, which is likely due to the early drop-out of
260 essential operons (Figure 4B).

261 At 48 hpi, we observed a strong population size reduction in both lung and blood samples, and the bottleneck
262 outcome was estimated to be as low as 25 bacterial cells responsible for causing disease (Figure 4C). CRISPRi
263 induction did not seem to have a substantial effect on bottleneck size estimations, suggesting that the bottleneck
264 selection effect overshadows the CRISPRi selection effect (Figure 4C). Surprisingly, bottleneck sizes varied
265 considerably between replicates and did not correlate between lung and blood samples of the same host (Figure 4C).
266 Moreover, there was little to no overlap in the different surviving strains in blood and lung samples within mice,
267 indicating independent bacterial survival in lung and blood invasion (Figure S3). Taken together, these observations
268 highlight the impact of bottlenecks on the outcomes of infection and strongly suggest that bacterial survival during
269 infection in the mouse pneumonia model is highly heterogenous and bacterial survival is a stochastic event.

270 Quantification of the abundance of each mutant can provide information about bacterial replication and
271 population expansion. To this end, we estimated the cell number of each mutant based on the abundance of each
272 sgRNA in the library and the bacterial load in both lung and blood of the mice on control feed (Figure 4D). Dramatic
273 stochastic changes in the genetic composition of the CRISPRi population were observed in all mice on control feed
274 for both lung and blood samples at 48 hpi (Figure 4D). In addition, there was no correlation of bacterial genetic
275 composition among samples from different mice, as individual mice have different dominant isogenic mutants. Most
276 strains have 0 sgRNA reads, indicating most bacteria were cleared from the lungs or failed to invade the bloodstream.
277 Some lowly abundant strains appear to have managed to survive, but not to actively multiply in both host niches, with
278 bacterial number estimates between 1-10. However, especially in the blood samples, some variants reached high cell
279 numbers (up to 10^7), suggesting that invasion by a few sgRNA strains was followed by rapid replication. High
280 replication rates in blood were further supported by observed bacterial loads in blood that were much higher than the
281 estimated bottleneck sizes (Figure S4). Lastly, mouse number 12 seems to be less competent in clearing bacteria from
282 the lung as clearly more variants survived, further stressing the importance of individual mouse effects despite being
283 an inbred mouse strain (Figure 4C, D). Notice that here we used a published population level doubling time estimate
284 (Opijnen and Camilli, 2012) for calculations of the bottleneck size. However, as described in Figure 4D, we observed
285 subpopulations with divergent behaviors, indicating high degrees of heterogeneity of bacterial growth in both lung

286 and blood during infection. This brings challenges for accurate estimation of doubling time at the population level.
 287 Different destinies of pneumococcal cells in the mouse infection model may be explained by bacterial phenotypic
 288 diversity or host-response diversity (Kreibich and Hardt, 2015). It has been determined that individual bacteria may
 289 occupy different micro-environments and can thus be exposed to dramatically different stimuli (Davis et al., 2015),
 290 which may contribute a level of randomness for certain pneumococcal clones to survive in the host. In addition, a
 291 single mouse passage can augment the virulence of some strains (Briles et al., 1981), such that within host evolution
 292 for genetic adaptation may lead to the emergence of subpopulations with different fates.

293
 294
 295



296
 297 **Figure 4. Exploring bottlenecks and pathogenesis of *S. pneumoniae* with CRISPRi-seq.** (A) Workflow of fitness
 298 cost and bottleneck evaluation in a mouse pneumonia model by CRISPRi-seq. (B) Bottleneck size of lung samples at
 299 24 hpi. 11 mice were treated with control chow, and 10 mice were treated with doxycycline chow. The horizontal red

300 dash line marks 14,990 bacterial cells, which is a 10-fold theoretical coverage of the CRISPRi library. The red
301 asterisks point to mouse #7 and mouse #9 in the control group. The bottleneck size of these two mice is lower than
302 10-fold of the library diversity. (C) Bottleneck size in lung and blood at 48 hpi. The black asterisks point out the lung
303 samples without successful collection of bacterial samples, which include mice without doxycycline treatment #1 and
304 #8, mice treated with doxycycline #2-dox, #3-dox, #7-dox, and #11-dox. (D) The number of bacteria barcoded with
305 different sgRNAs in the control group (no doxycycline treatment) was calculated according to the bacterial load and
306 sgRNA abundance in the population. Violin plots show the distribution of bacteria number in the lung samples (left
307 panel) and blood samples (right panel), each dot represents one bacterial variant. Notice that some mice were not
308 shown here, because the total bacterial load was below the limit of detection and the bacteria number of each variant
309 cannot be calculated.

310

311 **CRISPRi-seq screen at 24 hpi identifies PurA as essential in a mouse pneumonia model**


312 At 48 hpi, the effect of CRISPRi selection is overshadowed by a dramatic stochastic loss of mutants in the population
313 while passing through the bottleneck, and thus this timepoint cannot be used to evaluate the fitness of targets by
314 CRISPRi-seq (Figure 4C). However, earlier at 24 hpi, all mice except control mice numbers 7 and 9 exhibit a
315 bottleneck size greater than 10-fold of the diversity in the CRISPRi library. Additionally, the CRISPRi induction *in*
316 *vivo* clearly caused extra stress to the population, as the bottleneck size of the doxycycline-treated mice was smaller
317 than control mice (Figure 4B). We thus analyzed the fitness of target genes during lung infection based on the
318 sequencing data obtained at 24 hpi, excluding control mice numbers 7 and 9 (supplementary table S5).

319 *In vivo* fitness was compared to growth in laboratory media to identify those genes that became either more
320 or less essential during infection (Figure 5). There were 46 sgRNAs whose targets showed significantly differential
321 fitness between *in vivo* and *in vitro* conditions ($\log_2FC > 1$, $p_{adj} < 0.05$), including 31 sgRNAs whose targets were more
322 essential *in vivo* and 15 sgRNAs whose targets were less essential *in vivo* (supplementary table S5). Seeking to identify
323 novel virulence factors, we next focused on those genes that scored as more essential *in vivo*.

324 We selected 7 sgRNAs identified as targeting 13 neutral genes in C+Y laboratory growth media but predicted
325 essential *in vivo* with a $\log_2FC > 3$ difference (supplementary table S6). In line with the *in vitro* CRISPRi-seq data,
326 most of the targeted genes (8) could be deleted without a detectable growth defect in C+Y medium (Figure 6A). Note
327 that *spv_2285* was not tested, as it encodes a degenerate gene (Slager et al., 2018). However, *divIC* (targeted by
328 sgRNA0003), *spxA1* (sgRNA0464), and *dpr* (sgRNA0525) were identified as essential, since multiple attempts of
329 deletion failed, corroborating the results of other studies (Liu et al., 2017; van Opijnen et al., 2009). Interestingly, for
330 *pezT* and *pezA*, identified as an epsilon/zeta toxin-antitoxin system (Mutschler et al., 2011), single deletion of the toxin
331 gene *pezT* or double deletion of *pezA-T* system were achieved and the resulting mutants showed no growth defect
332 (Figure 6A). However, single deletion of the antitoxin gene *pezA* alone failed, an observation that indicates the *pezT*-
333 *A* toxin-antitoxin system is active under *in vitro* growth conditions.

334 Mice were then infected with the 8 viable knockout strains and the *pezA-T* double mutant individually by
335 intratracheal challenge, and the bacterial load in the lung of each mutant compared to wild-type strain D39V (Figure
336 6B). Among the 9 mutants, *purA* (targeted by sgRNA0005), which showed the biggest \log_2FC between infection and


337 C+Y medium in the CRISPRi-seq screen, was confirmed to be attenuated. sgRNA0005 targets an operon consisting
338 of *ccnC* and *purA*. Infection experiments with knockout and complementary strains of these two genes confirmed that
339 deletion of *purA*, but not *ccnC*, led to strongly attenuated *S. pneumoniae* virulence (Figure 6C). PurA, an
340 adenylosuccinate synthetase, was previously identified to have a virulence role in experimental pneumococcal
341 meningitis (Molzen et al., 2011). As adenylosuccinate synthetase is important for purine biosynthesis, we suspect the
342 attenuated virulence of the *purA* knockout mutant is caused by lack of purine availability in the corresponding *in vivo*
343 niches. To probe this further, we used a synthetic blood-like medium (BLM) (Aprianto et al., 2018) to propagate the
344 *purA* mutants. The *purA* knockout mutant did not show a growth defect in BLM medium supplemented with complete
345 nucleobases solution. However, specific reduction of adenine in the media led to marked growth retardation (Figure
346 6D).
347



348
349 **Figure 5. Comparison of fitness cost of gene depletion by CRISPRi by different sgRNAs between the mouse**
350 **lung infection model at 24 hpi and laboratory C+Y medium.** The difference was shown as the log₂ fold change
351 between the two conditions by DEseq2 analysis. The sgRNAs highlighted in red were the ones we selected for follow-
352 up confirmation studies.

353
354

Liu et al., 22 April 2020 – bioRxiv submission



355
 356 **Figure 6. PurA is an important pneumococcal gene during an *in vivo* murine pneumonia model.** (A) *In vitro*
 357 growth of the deletion mutants and the wild-type D39V strain in C+Y medium. Cell density was determined by
 358 measuring OD595nm every 10 minutes. The values represent averages of three replicates with SEM (same for panel
 359 D and E). (B-C) Mouse infection with individual mutants, compared to wild type D39V. Each dot represents a single
 360 mouse. Mean with SEM was plotted. (B) The mutants were tested in three batches of infection assays, for each assay
 361 the wild-type strain was tested in parallel. Significant difference between D39V and $\Delta purA$ was tested by Sidak's
 362 multiple comparisons test, and the adjusted *p* value is 0.0158. Although the *ccnC* mutant showed slightly less bacterial
 363 counts in this experiment, this was not statistically significant. (C) Validation study of sgRNA0005 targets, *ccnC* and
 364 *purA*. The virulence of deletion mutants and complementary strains were tested and compared to wild type D39V.
 365 There was a significant difference between the wild-type and $\Delta purA$ strain tested by Dunnett's multiple comparisons
 366 test, and the Adjusted *p* value is 0.0007. Note that ectopic expression of *purA* complemented the phenotype. (D)
 367 Growth of *purA* mutants in blood-like medium lacking adenine, adenosine, guanine, uracil, uridine, xanthine, and
 368 complete medium. (E) The pathway of S-adenosylmethionine (SAM) synthesis. (F) Growth of the *metK* deletion
 369 mutant in C+Y medium and C+Y medium supplemented with different concentrations of SAM.

370
371 ***In vitro* essential genes identified as non-essential *in vivo* highlight the power of CRISPRi-seq**
372 Out of the 15 sgRNAs whose targets were identified to be significantly less essential *in vivo* than in laboratory C+Y
373 medium, 11 sgRNAs were identified as essential in C+Y but neutral in lung infection (supplementary table S6). The
374 Ami oligopeptide permease, involved in uptake of environmental nutrients (Claverys et al., 2000), is encoded by the
375 *amiACDEF* operon. Interestingly, four sgRNAs targeting different genes of the Ami oligopeptide permease, *amiA*,
376 *aimC*, *aimE*, and *amiF*, were independently identified to be neutral in lung infection but essential in C+Y medium.
377 Consistent with these observations, Ami permease was previously reported to be conditionally essential and important
378 for nasopharyngeal colonization but not for pneumococcal lung infection (Kerr et al., 2004).

379 sgRNA0247, targeting *metK*, showed the most significant difference between *in vitro* and *in vivo* fitness
380 among this class of sgRNAs. The *metK* gene encodes S-adenosylmethionine synthetase, which catalyzes the formation
381 of S-adenosylmethionine (SAM) from methionine and ATP (Figure 6E). In line with its predicted function, the growth
382 defect of the *metK* deletion mutant in C+Y medium could be rescued by addition of S-adenosylmethionine (SAM),
383 with 1 μ M SAM completely restoring wild-type growth rate (Figure 6F). In human serum, the SAM level was reported
384 to be approximately 130 nM (Li et al., 2015). The nonessentiality of MetK in lung infection might be explained by
385 the presence of SAM in host tissue. A previous study showed that *Mycobacterium tuberculosis* cannot scavenge
386 intermediates of SAM and methionine biosynthesis from the host, and thus considered SAM- and methionine-related
387 pathways as potential new drug targets (Berney et al., 2015). However, for *S. pneumoniae*, our study indicates that
388 neither methionine nor SAM synthesis related pathway are essential for lung infection. Indeed, related sgRNAs, like
389 sgRNA0530 targeting *metB*, and sgRNA0193 targeting *metEF* were also seen to be neutral in infection (supplementary
390 table S5).

391 **Discussion**

392 The principal contribution of this study is the development of a concise pooled CRISPR interference system, aided by
393 the establishment of a new sgRNA assessment algorithm, suitable for high-throughput quantitative genetic interaction
394 screening on a genome-wide scale for the important human pathogen *S. pneumoniae*. A main advantage of this concise
395 doxycycline-inducible system is that it can be used for *in vivo* studies as the library size is small (1499 unique sgRNA)
396 so bacterial loads can be low and sequence depth does not need to be high. Using this system, we were able to map
397 infection bottlenecks in a murine model of pneumococcal pneumonia and show that as little as 25 individual bacterial
398 cells can cause systemic disease. In addition, CRISPRi-seq reveals that there is a large within host and between host
399 variability in dealing with pneumococcal infection, strongly suggesting that future work would benefit from a single
400 cell analytical approach to study towards pneumococcal infection. It would be interesting to see which host immune
401 response are most successful at increasing pathogen bottleneck sizes, and this information might inform on innovative
402 therapies.

403
404 Genes identified as essential in laboratory medium but neutral in the host provide information to refine the list of new
405 therapeutic targets for *S. pneumoniae*. For example, MetK, the SAM synthetase involved in SAM and methionine

406 pathways, was previously identified as potential drug target for *M. tuberculosis* (Berney et al., 2015). In contrast, our
407 study shows that MetK is not a promising target for pneumococcal disease since it is not essential *in vivo*. Another
408 example includes FOLD, which catalyzes the production of 10-formyltetrahydrofolate (10-formyl-THF). FOLD was
409 identified as neutral *in vivo* and essential in C+Y medium (supplementary table S5). The nonessentiality of FOLD in
410 the host may be explained by efficient production of 10-formyl-THF in mammalian cells (Ducker and Rabinowitz,
411 2017). In addition, our CRISPRi-seq screens showed that *metQ* and *metPN*, encoding the ABC transporter for
412 methionine, were not essential for *S. pneumoniae* survival during pneumonia, in line with a previous study that used
413 individual deletion mutants (Basavanna et al., 2013). Based on these corroborating observations, high-throughput *in*
414 *vivo* evaluation of fitness cost of genes by CRISPRi-seq can provide useful information on the nutrient requirements
415 during pneumococcal infection.

416
417 Out of the 7 sgRNAs that showed reduced *in vivo* fitness in the pooled CRISPRi-seq and were tested individually,
418 only *purA* was confirmed. The CRISPRi-seq screen is a competitive assay, which can amplify the fitness defect of
419 mutants. Some mutants that show attenuated virulence in competitive assays may have no such phenotype upon
420 individual infection (Basavanna et al., 2009, 2013), which may explain why other candidates were not confirmed in
421 the individual infection study. Alternatively, while at 24 hpi the sgRNA coverage was still greater than 10-fold that of
422 the library, the bacterial population is aggressively being cleared by the host innate immune system. Thus the assay
423 most strongly tests for mutants that are more or less resistance to host clearance rather than mutants that are attenuated
424 in replication. Regardless of their etiology, this study shows the existence of large bottlenecks in the commonly studied
425 pneumococcal mouse pneumonia model, such that from an initial inoculum of 10^7 bacteria, in some cases, only 25
426 single bacteria established systemic disease. This finding begs the question of how realistic this small animal system
427 is for modeling human pneumococcal pneumonia. Future studies might apply the CRISPRi-seq tool to other
428 established pneumococcal models of disease such as the influenza superinfection model, the zebrafish meningitis
429 model and the *Galleria mellonella* larvae invertebrate model (Cools et al., 2019; Jim et al., 2016; Rudd et al., 2016;
430 Saralahti et al., 2014).

431
432 In summary, the here presented concise CRISPRi-seq setup can be used for studying pneumococcal pneumonia,
433 including bottleneck exploration. The library, its design rules and the underlying bioinformatic approaches developed
434 here can now be expanded to study other infection-relevant conditions including testing of wild-type and knockout
435 mouse strains and evaluation of antibiotics and other therapeutic interventions and may serve as an example for studies
436 on other host-microbe interactions including human pathogens.

437
438

439 **Materials and Methods**

440 *Bacterial strains and growth medium*

441 *Streptococcus pneumoniae* D39V (Slager et al., 2018) was used as the parent strain for this study. C+Y medium
442 (pH=6.8), and Columbia agar plate supplied with 5% sheep blood were used to grow the strain and its derivatives.

443 Working stock of the pneumococcal cells, named as “T2 cells”, were prepared by collecting cells at OD₆₀₀ 0.3 and
444 then resuspending with fresh C+Y medium with 17% glycerol, and stored at -80°C. *Escherichia coli* stb13 was used
445 for subcloning of plasmids. LB agar with 100 µg/ml spectinomycin was used to select the *E. coli* transformants. Strains
446 and plasmids used in this study are listed in supplementary table S7. The oligos used for construction of mutants and
447 strains used in this study are listed and described in supplementary table S8.

448

449 *Construction of a tetracycline inducible (tet-inducible) CRISPRi system in S. pneumoniae D39V*

450 The tetracycline inducible CRISPRi system was constructed based on our previously published IPTG-inducible
451 CRISPRi system in *S. pneumoniae* (Liu et al., 2017) and a newly developed pneumococcal tet-inducible platform
452 (Sorg et al., 2019). First, a constitutively expressed pneumococcal codon-optimized *tetR* driven by promoter PF6 was
453 amplified from D-T-PEP9Ptet (Sorg et al., 2019) and integrated into the chromosome at the *prsI* locus in D39V strain,
454 resulting in strain VL2210. Three fragments were assembled to make the Ptet-*dcas9* construct for integration at the
455 *bgaA* locus. Fragment 1 containing upstream of *bgaA* and *tetM* was amplified from DCI23 (Liu et al., 2017) and
456 digested with XbaI; fragment 2 containing tet-inducible promoter PT4-1, here named Ptet, was amplified from plasmid
457 pPEP8T4-1 (Sorg et al., 2019), and digested with XbaI/NotI; fragment 3 containing the coding region of *dcas9* and
458 downstream of *bgaA* locus was amplified from strain DCI23 and digested with NotI. The three fragments were then
459 ligated followed by transformation into VL2210 by selecting with 1 µg/ml tetracycline, resulting in strain VL2212.

460

461 *Construction of the dual fluorescent reporter strain and confocal microscopy*

462 The codon optimized mNeonGreen was digested from pASR110 (pPEPZ-Plac-mNeonGreen) with BglII and XhoI
463 and cloned into pPEPY-Plac (Keller et al., 2019), followed by transformation into strain VL2212, resulting in strain
464 VL2339. The DNA fragment for insertion of *hlpA-mScarlet-I* was amplified from strain VL1780 (Kurushima et al.,
465 2020) and transformed into VL2339, resulting in the final dual fluorescent reporter strain VL2351. To verify
466 doxycycline levels were sufficient *in vivo* to induce inhibition via CRISPRi, mice were switched to feed containing
467 doxycycline (or control feed) two days prior to infection, and then infected with the reporter strain via intra-tracheal
468 infection, during which time mice remained on doxycycline feed (or control feed). At 48 hours post infection, whole
469 blood was collected via cardiac puncture followed by hypotonic lysis of red blood cells and subsequent resuspension
470 of remaining cells in PBS. Samples were placed on a glass slide, heat fixed and mounted in Cytoseal. Slides were
471 imaged using a Leica TCS SPE Confocal microscope with a 63X objective, LAS X acquisition software, and processed
472 using FIJI (Schindelin et al., 2012).

473

474 *Construction of knockout and complementary mutants in S. pneumoniae*

475 The erythromycin resistant marker, encoded by *eryR*, was used as selection marker for the knockout mutants. Three
476 fragments was assembled by Golden Gate cloning with either BsaI or BsmBI for each knockout mutant: Fragment 1
477 containing upstream of the target gene including its promoter sequence; fragment 2 containing *eryR* coding region
478 with RBS; fragment 3 containing downstream of the target gene. The assembled DNA fragment was then transformed
479 into D39V with 0.5 µg/ml erythromycin for selection. Notice that for making the $\Delta metK$ strain, 10 µM SAM was

Liu et al., 22 April 2020 – *bioRxiv* submission

480 supplemented in the agar plate. To make the complementary strains, the target gene with its native promoter was
481 amplified from genomic DNA of D39V and ligated with upstream and downstream homologous fragments of ZIP
482 locus followed by transformation into the knockout mutant with 100 µg/ml spectinomycin for selection. Primers used
483 here are listed in supplementary table S8.

484

485 Construction of the pooled CRISPRi library

486 *Construction of vector pPEPZ-sgRNAclone for sgRNA cloning by Golden Gate cloning*

487 Integration vector pPEPZ (Keller et al., 2019) was used as backbone. A gBlock containing Illumina read 1 sequence,
488 P3 promoter, *mCherry* flanking with BsmBI sites, dCas9 handle binding and terminator region of sgRNA, Illumina
489 read 2 sequence, 8 bp Illumina index sequence and P7 adaptor sequence in order, was synthesized by Integrated DNA
490 Technologies (IDT). In this design, *mCherry* provides the sgRNA base-pairing cloning sites and will be replaced with
491 20 bp specific sequence for targeting different genes. The Illumina sequences across the sgRNA cloning sites work as
492 primer binding handles for one-step PCR amplification of the sgRNA sequence, in order to prepare amplicon library
493 for Illumina sequencing. The gBlock was digested with BamHI/XhoII, and then ligated with BamHI/XhoII digested
494 pPEPZ, followed by transformation into *E. coli* stb13 selected with 100 µg/ml spectinomycin. The *E. coli* strain with
495 this vector forms bright red colonies. The vector pPEPZ-sgRNAclone was deposited at Addgene (catalog #141090).

496

497 *Selection of sgRNAs for each operon*

498 Primary operons (pTSS operons) were annotated in *S. pneumoniae* D39V strain in a previous study (Slager et al.,
499 2018). First, for all the identified pTSS operons, one sgRNA with high specificity and close proximity to the pTSS
500 was designed for each operon. For genes that are not covered by pTSS operons, one sgRNA was selected for each
501 gene. *S. pneumoniae* has multiple types of repeat regions, such as BOX elements, Repeat Units of the Pneumococcus
502 (RUP), SPRITEs and IS elements (Slager et al., 2018). There are some sgRNAs targeting genes located in repeat
503 regions, and as such these sgRNAs have multiple targeting sites. The sgRNAs and targets are listed in supplementary
504 table S1. Post-hoc target identification, including off-target sites, was performed with a custom R script
505 (<https://github.com/veeninglab/CRISPRi-seq>), of which the results are shown in supplementary table S2 and analyzed
506 separately (<https://www.veeninglab.com/crispri-seq>, “Pneumococcal sgRNA library efficiency exploration”).

507

508 *Cloning of sgRNAs by Golden Gate cloning*

509 Two oligos were designed for each sgRNA (Figure 2). The two oligos were then annealed in TEN buffer (10 mM
510 Tris, 1 mM EDTA, 100 mM NaCl, pH 8) in a thermocycler, 95°C for 5 minutes followed by slowly cooling down to
511 room temperature. The annealed oligos were then pooled together at equimolar concentration, followed by
512 phosphorylation with T4 polynucleotide kinase (New England Biolabs). The vector pPEPZ-sgRNAclone was digested
513 with BsmBI and carefully purified by gel extraction to ensure removal of the *mCherry* fragment. The annealed oligos
514 and digested pPEPZ-sgRNAclone were then ligated with T4 ligase, followed by transformation into *E. coli* stb13 and
515 selected with 100 µg/ml spectinomycin on LB agar plates. In total, more than 70,000 individual transformant colonies
516 were obtained and collected, providing about a 50 fold theoretical coverage of the 1499 sgRNAs. No red colonies

517 were visually present, indicating a very low false positive rate of the cloning. The oligos for cloning of sgRNAs are
518 listed in supplementary table S8.

519

520 *Construction of the pooled CRISPRi library in S. pneumoniae D39V*

521 Plasmids from the *E. coli* library with the sgRNA pool were isolated, and transformed into *S. pneumoniae* VL2212
522 (this study) and DCI23 (Liu et al., 2017) to construct tet-inducible and IPTG-inducible CRISPRi-seq libraries,
523 respectively. More than 10^7 individual transformant colonies were obtained and collected for both of the strains.

524

525 *CRISPRi-seq screen in laboratory medium*

526 The screen was done over about 21 generations of growth in triplicates. The pooled libraries were grown in C+Y
527 medium at 37°C to $OD_{595}=0.3$ as preculture. Then, the precultures were diluted 1:100 into C+Y medium with or
528 without inducer, 1 mM IPTG or 10 ng/ml doxycycline. When OD_{595} reached 0.3, cultures were diluted into fresh
529 medium by 1:100 again. Another 1:100 dilution was done in the same fashion, so in total three times of 1:100 dilution,
530 ensuring about 21 generations of induction and competition (doubling time of approximately 26 min). Bacteria were
531 collected when $OD_{595}=0.3$ after the third dilution, and the pellets were used for gDNA isolation with the Wizard
532 Genomic DNA Purification Kit (Promega) as described previously (Liu et al., 2017). The fitness evaluated by IPTG-
533 or tet- inducible library is listed in supplementary table S3.

534

535 *CRISPRi-seq screen in a mouse pneumonia model*

536 The UCSD Institutional Animal Care and Use Committee approved all animal use and procedures (protocol number
537 S00227M, Victor Nizet). Two days prior to infection, 6-8 week old female BALB/c mice (Jackson Laboratories -
538 000651) were fed control feed or 200 ppm doxycycline feed *ad libitum* (Envigo TD.120769, with blue food coloring),
539 allowing serum concentrations of doxycycline to stabilize prior to infection (Redelsperger et al., 2016). Bacterial
540 libraries were grown *in vitro* in C+Y medium in the absence of selection (i.e. no doxycycline) to an OD_{600} of 0.4,
541 sonicated for 3 seconds to break up clumps, and then resuspended in PBS at a concentration of 1×10^8 CFU per 30
542 μ L. Mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine (intraperitoneal administration), vocal
543 cords were visualized with an otoscope and 30 μ L bacteria was delivered into the lungs by pipetting. Mice were
544 returned to the same cages after infection, containing doxycycline or control feed. At 24 or 48 hpi, mice were
545 euthanized via CO₂ asphyxiation, lungs were dissected and homogenized in 1 mL PBS, while blood was collected by
546 cardiac puncture in the presence of EDTA to prevent clotting. Following tissue harvest, lung homogenate or blood
547 was diluted in 15 mL C+Y medium (without selection), incubated at 37 °C with 5% CO₂ until cultures reached an
548 OD_{600} of 0.4. Samples were then pelleted and frozen before subsequent gDNA isolation and sequencing. For the
549 comparison of fitness between mice infection model and C+Y medium, please refer to supplementary table S5.

550

551

552 *sgRNA library target and efficiency evaluation*

553 All potential sgRNA binding sites on the *S. pneumoniae* D39V genome were identified using the R package
554 CRISPRseek (Zhu et al., 2014), taking into account PAM presence and allowing up to eight mismatches between
555 spacers and genome. We set the maximum number of allowed mismatches to eight, because of (1) the exponential
556 growth of computation time with this parameter and (2) any potential effect on a site with >8 mismatches was assumed
557 to be negligible. The *S. pneumoniae* D39V genome (Slager et al., 2018) was downloaded from NCBI (CP027540.1)
558 and read into R using the biomart package (Drost and Paszkowski, 2017). All identified binding sites can be found
559 in supplementary table S2.

560 In addition to the standard CRISPRseek output, we assessed for each binding site if it overlapped with any
561 genetic element annotated with a *locus_tag* key in the GFF file on the non-template (NT) strand. If any, the locus tag
562 was added to the table (“NTgene”), as well as which part of the sgRNA corresponding to that binding site was
563 overlapping (“coverPart”: complete, 5’- or 3’-end) and with how many base pairs (“coverSize”) including the PAM.
564 In case one binding site overlapped multiple annotated elements, both were inserted as a row in the table, with
565 matching “site” numbers.

566 Furthermore, we estimated the relative retained repression activity (“reprAct”) of each sgRNA binding site
567 compared to a hypothetical zero-mismatch binding site on the same locus, based on the mismatches with the sgRNA
568 spacer. Retained repression activity depends on both the number and the within-spacer position of mismatches (Qi et
569 al., 2013). Furthermore, the retained activity for an sgRNA with two adjacent mismatches appears to be the product
570 of their individual retained scores, relative to a zero-mismatch silencing effect (Qi et al., 2013). We assumed this
571 multiplication principle also holds for >2 and non-adjacent mismatches. Therefore, we computed per sgRNA, per
572 binding site, the expected repression activity as the product of the nucleotide-specific retained activity scores as
573 reported by Qi et al. (2013), estimated from their Figure 5D and averaged over the three intra-spacer regions they
574 defined (Qi et al., 2013). The resulting score represents the estimated retained repression activity of the sgRNA on the
575 binding site, relative to an hypothetical binding site for the same sgRNA on the same chromosomal locus, on the [0,1]
576 interval.

577 According to this method, the maximum repression effect of any site with >8 mismatches would be 0.77%
578 of the hypothetical zero-mismatch effect. This was indeed considered negligible, supporting our decision to only
579 consider sgRNA binding sites with eight mismatches or less.

580 Lastly, we added to the table the relative distance of the binding site to the start codon of the genetic element
581 it binds to, if any (“dist2SC”). This distance is normalized to the [0,1] interval using feature scaling, where a distance
582 of 0 means binding on the start codon or partially overlap with the 5’-end of the element, and a distance of 1 means
583 binding at or partial overlap with the far 3’-end of the element. Smaller distances are associated with more efficient
584 transcription repression (Qi et al., 2013).

585 The custom R script used to produce this table can be found on Github
586 (<https://github.com/veeninglab/CRISPRi-seq>). The script is written in a generic way, allowing to run the complete
587 pipeline described above for any given NCBI genome, as we did for *S. pneumoniae* strains TIGR4 (AE005672.3), R6
588 (AE007317.1), Hungary19A-6 (CP000936.1), Taiwan19F-14 (CP000921.1), 11A (CP018838.1) and G54

589 (CP001015.1). Results tables and analysis of these genomes can be found on the Veeninglab website
590 (<https://www.veeninglab.com/crispri-seq>).

591

592 *Library preparation, sequencing and data analysis*

593 The Illumina libraries were prepared by one-step PCR with oligos listed in supplementary table S8. The isolated
594 gDNAs of *S. pneumoniae* were used as template for PCR. The index 1, index 2 and adapter sequence were introduced
595 by this one-step PCR. For each 50 μ l of PCR reaction, 4 μ g of gDNA was used as input template, which enables us to
596 obtain sufficient PCR products with as little as 8 cycles of PCR. In addition, we have tested 10 cycles, 20 cycles and
597 30 cycles of PCR reaction, and no significant difference was observed (data not shown), indicating no detectable bias
598 introduced by PCR. The amplicons (304 bp) were then purified from a 2% agarose gel. Concentrations of amplicons
599 were then determined by a Qubit assay (Q32854, ThermoFisher Scientific). Purified amplicons were sequenced on a
600 MiniSeq (Illumina) with a custom sequencing protocol. The first 54 cycles for sequencing of common sequence of
601 amplicons were set as dark cycles, and the following 20 cycles were used for sequencing of the diversified base-
602 pairing region of sgRNA. The fastq files generated from sequencing are uploaded to the Sequence Read Archive
603 (SRA) on NCBI with accession number PRJNA611488.

604 The 20 bp base-pairing sequences were trimmed out from read 1 according to their position with
605 Trimmomatic Version 0.36 (Bolger et al., 2014). To map the sgRNA sequences, a pseudogenome containing all the
606 sgRNA sequences was prepared, and the sgRNA sequences on the pseudogenome were annotated with sgRNA
607 numbers, 1 to 1499. Then the trimmed reads were mapped to the pseudogenome with Bowtie 2 (Langmead and
608 Salzberg, 2012). The sgRNAs were counted with featureCounts (Liao et al., 2014). The count data of sgRNAs were
609 then analyzed with the DESeq2 package in R for evaluation of fitness cost of each sgRNA. We tested against a log₂FC
610 of 1, with an alpha of 0.05. Whenever log₂FC are visualized or reported, these are shrunk with the apeglm method.
611 The R script used for analysis is available at <https://github.com/veeninglab/CRISPRi-seq>. The size of infection
612 bottlenecks was calculated as reported previously (Abel et al., 2015). The doubling time of *S. pneumoniae* used in the
613 calculation was based on a previous Tn-seq study (Opijnen and Camilli, 2012) as 108 minutes.

614

615 *Growth assays and luciferase assay*

616 For Figure 1B, 6A and 6F, the working stock of each mutant, T2 cells, were thawed and diluted 1:100 into fresh C+Y
617 medium, or C+Y medium with doxycycline at different final concentrations, or with different concentrations of S-(5'-
618 Adenosyl)-L-methionine (A7007, Sigma Aldrich), as the initial cell culture. For Figure 6D, the T2 cells were thawed
619 and diluted 1:100 into fresh Blood Like Medium (BLM) without nucleobases solution, or supplemented with
620 individual nucleobases component (adenine, adenosine, guanine, uracil, uridine and xanthine), or with all the
621 components (Aprianto et al., 2018). Then 300 μ l of the initial culture was aliquoted into each well of 96-well plates
622 with 3 replicates. Cell density were monitored by measuring OD₅₉₅ every 10 minutes with a Tecan Spark microtiter
623 plate reader at 37°C. Luciferase assay (Figure 1B) was performed as previously described (Liu et al., 2017). Luciferin
624 (D-Luciferin sodium salt, SYNCHEM OHG) was added into C+Y medium at final concentration of 450 μ g/ml as
625 substrate of the luciferase. Luminescence signal were measured every 10 minutes with a Tecan Spark microtiter plate.

626 The growth curve and luciferase activity curve were plotted with GraphPad Prism 8 as described previously (Sorg and
627 Veening, 2015).

628 **Author Contributions and Notes**

629 X.L, J.M.K and J.W.V designed research, X.L. and J.M.K performed research, V.D.B. wrote the R script for sgRNA
630 evaluation and DEseq2 analysis, X.L, J.M.K, V.D.B, V.N and J.W.V analyzed data; and X.L, J.M.K, V.D.B, V.N and
631 J.W.V wrote the paper. The authors declare no conflict of interest.

632 This article contains supporting information online.

633 **Acknowledgments**

634 We are grateful to Lance Keller for critical reading of the manuscript. We appreciate all members of the Veening lab for stimulating
635 discussions. This work was supported by the Swiss National Science Foundation (SNSF) (project grant 31003A_172861 to J.W.V.)
636 and JPIAMR grant (40AR40_185533 to J.W.V.) from SNSF. Work in the Nizet lab is supported by NIH grant A1145325. J.M.K.
637 was supported by the University of California President's Postdoctoral Fellowship Program (UC PFP).

638

639 **References**

640 Abel, S., Abel zur Wiesch, P., Chang, H.-H., Davis, B.M., Lipsitch, M., and Waldor, M.K. (2015). Sequence tag-based analysis of
641 microbial population dynamics. *Nat. Methods* *12*, 223–226.

642 Aprianto, R., Slager, J., Holsappel, S., and Veening, J.-W. (2018). High-resolution analysis of the pneumococcal transcriptome
643 under a wide range of infection-relevant conditions. *Nucleic Acids Res.* *46*, 9990–10006.

644 Basavanna, S., Khandavilli, S., Yuste, J., Cohen, J.M., Hosie, A.H.F., Webb, A.J., Thomas, G.H., and Brown, J.S. (2009). Screening
645 of *Streptococcus pneumoniae* ABC Transporter Mutants Demonstrates that LivJHMGF, a Branched-Chain Amino Acid ABC
646 Transporter, Is Necessary for Disease Pathogenesis. *Infect. Immun.* *77*, 3412–3423.

647 Basavanna, S., Chimalapati, S., Maqbool, A., Rubbo, B., Yuste, J., Wilson, R.J., Hosie, A., Ogunniyi, A.D., Paton, J.C., Thomas,
648 G., et al. (2013). The effects of methionine acquisition and synthesis on *Streptococcus pneumoniae* growth and virulence. *PLoS*
649 *One* *8*, e49638.

650 Berney, M., Berney-Meyer, L., Wong, K.-W., Chen, B., Chen, M., Kim, J., Wang, J., Harris, D., Parkhill, J., Chan, J., et al. (2015).
651 Essential roles of methionine and S-adenosylmethionine in the autarkic lifestyle of *Mycobacterium tuberculosis*. *Proc. Natl. Acad.*
652 *Sci. U. S. A.* *112*, 10008–10013.

653 Bikard, D., Jiang, W., Samai, P., Hochschild, A., Zhang, F., and Marraffini, L.A. (2013). Programmable repression and activation
654 of bacterial gene expression using an engineered CRISPR-Cas system. *Nucleic Acids Res.* *41*, 7429–7437.

655 Bolger, A.M., Lohse, M., and Usadel, B. (2014). Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinforma. Oxf.*
656 *Engl.* *30*, 2114–2120.

657 Briles, D.E., Nahm, M., Schroer, K., Davie, J., Baker, P., Kearney, J., and Barletta, R. (1981). Antiphosphocholine antibodies found
658 in normal mouse serum are protective against intravenous infection with type 3 *Streptococcus pneumoniae*. *J. Exp. Med.* *153*, 694–
659 705.

660 Burdett, V. (1996). Tet(M)-promoted release of tetracycline from ribosomes is GTP dependent. *J. Bacteriol.* *178*, 3246–3251.

661 Chen, H., Ma, Y., Yang, J., O'Brien, C.J., Lee, S.L., Mazurkiewicz, J.E., Haataja, S., Yan, J.-H., Gao, G.F., and Zhang, J.-R.
662 (2007). Genetic requirement for pneumococcal ear infection. *PLoS One* *3*, e2950.

- 663 Chiavolini, D., Pozzi, G., and Ricci, S. (2008). Animal Models of *Streptococcus pneumoniae* Disease. *Clin. Microbiol. Rev.* *21*,
664 666–685.
- 665 Claverys, J.P., Grossiord, B., and Alloing, G. (2000). Is the Ami-AliA/B oligopeptide permease of *Streptococcus pneumoniae*
666 involved in sensing environmental conditions? *Res. Microbiol.* *151*, 457–463.
- 667 Cools, F., Torfs, E., Aizawa, J., Vanhoutte, B., Maes, L., Caljon, G., Delputte, P., Cappoen, D., and Cos, P. (2019). Optimization
668 and Characterization of a *Galleria mellonella* Larval Infection Model for Virulence Studies and the Evaluation of Therapeutics
669 Against *Streptococcus pneumoniae*. *Front. Microbiol.* *10*, 311.
- 670 Cui, L., Vigouroux, A., Rousset, F., Varet, H., Khanna, V., and Bikard, D. (2018). A CRISPRi screen in *E. coli* reveals sequence-
671 specific toxicity of dCas9. *Nat. Commun.* *9*, 1912.
- 672 Davis, K.M., Mohammadi, S., and Isberg, R.R. (2015). Community behavior and spatial regulation within a bacterial microcolony
673 in deep tissue sites serves to protect against host attack. *Cell Host Microbe* *17*, 21–31.
- 674 Dönhöfer, A., Franckenberg, S., Wickles, S., Berninghausen, O., Beckmann, R., and Wilson, D.N. (2012). Structural basis for
675 TetM-mediated tetracycline resistance. *Proc. Natl. Acad. Sci.* *109*, 16900–16905.
- 676 Drost, H.G., and Paszkowski, J. (2017). Biomart: Genomic data retrieval with R. *Bioinformatics* *33*, 1216–1217.
- 677 Ducker, G.S., and Rabinowitz, J.D. (2017). One-Carbon Metabolism in Health and Disease. *Cell Metab.* *25*, 27–42.
- 678 Gerlini, A., Colomba, L., Furi, L., Braccini, T., Manso, A.S., Pammolli, A., Wang, B., Vivi, A., Tassini, M., Rooijen, N. van, et al.
679 (2014). The Role of Host and Microbial Factors in the Pathogenesis of Pneumococcal Bacteraemia Arising from a Single Bacterial
680 Cell Bottleneck. *PLOS Pathog.* *10*, e1004026.
- 681 Hava, D.L., and Camilli, A. (2002). Large-scale identification of serotype 4 *Streptococcus pneumoniae* virulence factors:
682 Pneumococcal virulence factors. *Mol. Microbiol.* *45*, 1389–1406.
- 683 Jiang, W., Oikonomou, P., and Tavazoie, S. (2020). Comprehensive Genome-wide Perturbations via CRISPR Adaptation Reveal
684 Complex Genetics of Antibiotic Sensitivity. *Cell* *180*, 1002-1017.e31.
- 685 Jim, K.K., Engelen-Lee, J., van der Sar, A.M., Bitter, W., Brouwer, M.C., van der Ende, A., Veening, J.-W., van de Beek, D., and
686 Vandenbroucke-Grauls, C.M.J.E. (2016). Infection of zebrafish embryos with live fluorescent *Streptococcus pneumoniae* as a real-
687 time pneumococcal meningitis model. *J. Neuroinflammation* *13*, 188.
- 688 Keller, L.E., Rueff, A.-S., Kurushima, J., and Veening, J.-W. (2019). Three New Integration Vectors and Fluorescent Proteins for
689 Use in the Opportunistic Human Pathogen *Streptococcus pneumoniae*. *Genes* *10*, 394.
- 690 Kerr, A.R., Adrian, P.V., Estevão, S., de Groot, R., Alloing, G., Claverys, J.-P., Mitchell, T.J., and Hermans, P.W.M. (2004). The
691 Ami-AliA/AlIB permease of *Streptococcus pneumoniae* is involved in nasopharyngeal colonization but not in invasive disease.
692 *Infect. Immun.* *72*, 3902–3906.
- 693 Kono, M., Zafar, M.A., Zuniga, M., Roche, A.M., Hamaguchi, S., and Weiser, J.N. (2016). Single Cell Bottlenecks in the
694 Pathogenesis of *Streptococcus pneumoniae*. *PLOS Pathog.* *12*, e1005887.
- 695 Kreibich, S., and Hardt, W.-D. (2015). Experimental approaches to phenotypic diversity in infection. *Curr. Opin. Microbiol.* *27*,
696 25–36.
- 697 Kurushima, J., Campo, N., van Raaphorst, R., Cerckel, G., Polard, P., and Veening, J.-W. (2020). Unbiased homeologous
698 recombination during pneumococcal transformation allows for multiple chromosomal integration events. *bioRxiv*
699 10.1101/2020.03.15.992354.
- 700 Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. *Nat. Methods* *9*, 357–359.
- 701 Lau, G.W., Haataja, S., Lonetto, M., Kensit, S.E., Marra, A., Bryant, A.P., McDevitt, D., Morrison, D.A., and Holden, D.W. (2001).
702 A functional genomic analysis of type 3 *Streptococcus pneumoniae* virulence: Functional genomics of *Streptococcus pneumoniae*.
703 *Mol. Microbiol.* *40*, 555–571.

Liu et al., 22 April 2020 – *bioRxiv* submission

- 704 Lee, H.H., Ostrov, N., Wong, B.G., Gold, M.A., Khalil, A.S., and Church, G.M. (2019). Functional genomics of the rapidly
705 replicating bacterium *Vibrio natriegens* by CRISPRi. *Nat. Microbiol.* 1.
- 706 Li, T., Yu, G., Guo, T., Qi, H., Bing, Y., Xiao, Y., Li, C., Liu, W., Yuan, Y., He, Y., et al. (2015). The Plasma S-adenosylmethionine
707 Level is Associated With the Severity of Hepatitis B-Related Liver Disease. *Medicine (Baltimore)* 94.
- 708 Li, Y., Thompson, C.M., Trzcinski, K., and Lipsitch, M. (2013). Within-Host Selection Is Limited by an Effective Population of
709 *Streptococcus pneumoniae* during Nasopharyngeal Colonization. *Infect. Immun.* 81, 4534–4543.
- 710 Liao, Y., Smyth, G.K., and Shi, W. (2014). featureCounts: an efficient general purpose program for assigning sequence reads to
711 genomic features. *Bioinforma. Oxf. Engl.* 30, 923–930.
- 712 Liu, X., Gallay, C., Kjos, M., Domenech, A., Slager, J., Kessel, S.P. van, Knoops, K., Sorg, R.A., Zhang, J.-R., and Veening, J.-
713 W. (2017). High-throughput CRISPRi phenotyping identifies new essential genes in *Streptococcus pneumoniae*. *Mol. Syst. Biol.*
714 13, 931.
- 715 Molzen, T.E., Burghout, P., Bootsma, H.J., Brandt, C.T., van der Gaast-de Jongh, C.E., Eleveld, M.J., Verbeek, M.M., Frimodt-
716 Møller, N., Østergaard, C., and Hermans, P.W.M. (2011). Genome-Wide Identification of *Streptococcus pneumoniae* Genes
717 Essential for Bacterial Replication during Experimental Meningitis. *Infect. Immun.* 79, 288–297.
- 718 Mutschler, H., Gebhardt, M., Shoeman, R.L., and Meinhart, A. (2011). A Novel Mechanism of Programmed Cell Death in Bacteria
719 by Toxin–Antitoxin Systems Corrupts Peptidoglycan Synthesis. *PLoS Biol.* 9.
- 720 van Opijnen, T., and Camilli, A. (2012). A fine scale phenotype–genotype virulence map of a bacterial pathogen. *Genome Res.* 22,
721 2541–2551.
- 722 van Opijnen, T., Bodi, K.L., and Camilli, A. (2009). Tn-seq: high-throughput parallel sequencing for fitness and genetic interaction
723 studies in microorganisms. *Nat. Methods* 6, 767–772.
- 724 Peters, J.M., Colavin, A., Shi, H., Czarny, T.L., Larson, M.H., Wong, S., Hawkins, J.S., Lu, C.H.S., Koo, B.-M., Marta, E., et al.
725 (2016). A Comprehensive, CRISPR-based Functional Analysis of Essential Genes in Bacteria. *Cell* 165, 1493–1506.
- 726 van der Poll, T., and Opal, S.M. (2009). Pathogenesis, treatment, and prevention of pneumococcal pneumonia. *The Lancet* 374,
727 1543–1556.
- 728 Qi, L.S., Larson, M.H., Gilbert, L.A., Doudna, J.A., Weissman, J.S., Arkin, A.P., and Lim, W.A. (2013). Repurposing CRISPR as
729 an RNA-guided platform for sequence-specific control of gene expression. *Cell* 152, 1173–1183.
- 730 Redelsperger, I.M., Taldone, T., Riedel, E.R., Lephherd, M.L., Lipman, N.S., and Wolf, F.R. (2016). Stability of Doxycycline in
731 Feed and Water and Minimal Effective Doses in Tetracycline-Inducible Systems. *J. Am. Assoc. Lab. Anim. Sci. JAALAS* 55, 467–
732 474.
- 733 Rudd, J.M., Ashar, H.K., Chow, V.T., and Teluguakula, N. (2016). Lethal Synergism between Influenza and *Streptococcus*
734 *pneumoniae*. *J. Infect. Pulm. Dis.* 2.
- 735 Saralahti, A., Piippo, H., Parikka, M., Henriques-Normark, B., Rämetsä, M., and Rounioja, S. (2014). Adult zebrafish model for
736 pneumococcal pathogenesis. *Dev. Comp. Immunol.* 42, 345–353.
- 737 Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Preibisch, S., Rueden, C., Saalfeld, S., Schmid,
738 B., et al. (2012). Fiji: an open-source platform for biological-image analysis. *Nat. Methods* 9, 676–682.
- 739 Slager, J., Aprianto, R., and Veening, J.W. (2018). Deep genome annotation of the opportunistic human pathogen *Streptococcus*
740 *pneumoniae* D39. *Nucleic Acids Res.* 46, 9971–9989.
- 741 Sorg, R.A., and Veening, J.-W. (2015). Microscale insights into pneumococcal antibiotic mutant selection windows. *Nat. Commun.*
742 6, 8773.
- 743 Sorg, R.A., Gallay, C., and Veening, J.-W. (2019). Synthetic gene regulatory networks in the opportunistic human pathogen
744 *Streptococcus pneumoniae*. *bioRxiv* 10.1101/834689.

- 745 Wang, T., Guan, C., Guo, J., Liu, B., Wu, Y., Xie, Z., Zhang, C., and Xing, X.-H. (2018). Pooled CRISPR interference screening
746 enables genome-scale functional genomics study in bacteria with superior performance. *Nat. Commun.* *9*, 2475.
- 747 Weiser, J.N., Ferreira, D.M., and Paton, J.C. (2018). *Streptococcus pneumoniae* : transmission, colonization and invasion. *Nat.*
748 *Rev. Microbiol.* *1*.
- 749 de Wet, T.J., Gobe, I., Mhlanga, M.M., and Warner, D.F. (2018). CRISPRi-Seq for the Identification and Characterisation of
750 Essential Mycobacterial Genes and Transcriptional Units (*Microbiology*).
- 751 Zhu, L.J., Holmes, B.R., Aronin, N., and Brodsky, M.H. (2014). CRISPRseek: A Bioconductor package to identify target-specific
752 guide RNAs for CRISPR-Cas9 genome-editing systems. *PLoS ONE* *9*.
- 753
- 754